199 related articles for article (PubMed ID: 36970051)
21. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy.
Zhu H; Leiss L; Yang N; Rygh CB; Mitra SS; Cheshier SH; Weissman IL; Huang B; Miletic H; Bjerkvig R; Enger PØ; Li X; Wang J
Oncotarget; 2017 Feb; 8(7):12145-12157. PubMed ID: 28076333
[TBL] [Abstract][Full Text] [Related]
22. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
23. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
[TBL] [Abstract][Full Text] [Related]
24. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
[TBL] [Abstract][Full Text] [Related]
25. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
[TBL] [Abstract][Full Text] [Related]
26. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
27. Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis.
Park HR; Kim SE; Keam B; Chung H; Seok SH; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
Sci Rep; 2022 Jul; 12(1):12546. PubMed ID: 35869130
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors.
Liu Y; Xue R; Duan X; Shang X; Wang M; Wang F; Zhu L; Zhang L; Ge X; Zhao X; Guo H; Wang Z; Zhang L; Gao X; Shen A; Sheng Y; Qin Z
Life Sci; 2023 Aug; 326():121790. PubMed ID: 37211345
[TBL] [Abstract][Full Text] [Related]
29. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
30. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
31. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
32. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
33. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
34. The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.
Zhuang Z; Zhou J; Qiu M; Li J; Lin Z; Yi H; Liu X; Huang C; Tang B; Liu B; Li X
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398223
[TBL] [Abstract][Full Text] [Related]
35. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.
Lu J; Li J; Lin Z; Li H; Lou L; Ding W; Ouyang S; Wu Y; Wen Y; Chen X; Yue P; Wang Y; Liu P; Lu J; Zhang J; Feng W; Zhang X
Cancer Lett; 2023 Jun; 564():216205. PubMed ID: 37146936
[TBL] [Abstract][Full Text] [Related]
36. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
37. Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice.
Abe T; Tanaka Y; Piao J; Tanimine N; Oue N; Hinoi T; Garcia NV; Miyasaka M; Matozaki T; Yasui W; Ohdan H
Ann Gastroenterol Surg; 2018 Nov; 2(6):451-462. PubMed ID: 30460349
[TBL] [Abstract][Full Text] [Related]
38. The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions.
Osorio JC; Smith P; Knorr DA; Ravetch JV
Cancer Cell; 2023 Dec; 41(12):2051-2065.e6. PubMed ID: 37977147
[TBL] [Abstract][Full Text] [Related]
39. Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy.
Ramesh A; Kumar S; Nguyen A; Brouillard A; Kulkarni A
Nanoscale; 2020 Jan; 12(3):1875-1885. PubMed ID: 31903467
[TBL] [Abstract][Full Text] [Related]
40. A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety.
Li Y; Liu J; Chen W; Wang W; Yang F; Liu X; Sheng Y; Du K; He M; Lyu X; Li H; Zhao L; Wei Z; Wang F; Zheng S; Sui J
J Hematol Oncol; 2023 Jan; 16(1):2. PubMed ID: 36650558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]